LCTX

0.77195.87%
AC

Angus C. Russell

Independent Director

Mr. Angus C. Russell serves as Member of Strategic Advisory Board at Coherus Oncology, Inc. (formerly known as Coherus BioSciences, Inc.) since September 2023. He serves as Member of Advisory Board at Antibe Therapeutics Inc. since October 2018. He serves as the Chief Executive Officer of Regenerative Medicine (RM) Business at Shire Regenerative Medicine, Inc. Mr. Russell serves as the Chairman of Shire?s Leadership Team. He is a veteran in the global biopharmaceutical industry with extensive experience in commercial execution, operations and strategic acquisitions. He has experience as an officer and Director in the specialty pharmaceutical industry. He served as the Chief Executive Officer at Shire plc from June 18, 2008 to April 30, 2013 and served as its Interim President of Specialty Pharma until April 30, 2013. He served as the Chief Financial Officer of Shire plc from December 1999 to June 2008 and also served as its Principal Accounting Officer and Executive Vice President of Global Finance. He served as the Chairman of Shire?s Leadership. He joined Shire on December 13, 1999 and served as its Group Finance Director and was responsible for finance, IS, risk management, corporate communications and Investor Relations. Prior to joining Shire, he worked for ICI, Zeneca and AstraZeneca PLC. He joined ICI?s Pharmaceuticals Divisions in a management accounting role and subsequently a production accounting role. He transferred to Corporate Planning Department, where he worked on several global business strategies, executed a number of M&A deals, co-ordinated defense work and oversaw business activities in The Americas, Middle East, Africa, India and Pakistan. He served as the Vice President of Corporate Finance at AstraZeneca PLC, where he was responsible for financial input into mergers and acquisitions activities, management of tax, legal and finance structure, Investor Relation?s activities and the management of various financial risks. In 1999, he was a part of a small team, which negotiated the Syngenta agrochemicals merger with Novartis. He held a number of positions within Zeneca Group PLC from 1993 to 1999, including Group Treasurer. He served at ICI from 1980 to 1992 with responsibility for Treasury, Investor Relations and IC Insurance. He had been the Chairman and Director of Revance Therapeutics, Inc. since March 4, 2014. He had been an Independent Director at Mallinckrodt plc since August 14, 2014 until June 2022 and had been its Chairman of the Board since May 16, 2018 until June 2022. He serves as a Director of Shire Acquisition Inc. He had been an Independent Director at TherapeuticsMD, Inc. from March 18, 2015 until December 2022. Mr. Russell has been an Independent Director of Lineage Cell Therapeutics, Inc. (formerly known as BioTime, Inc.) since December 2014. He joined the Lineage Cell Therapeutics, Inc. in December 2014. He serves as a Member of the Advisory Board of Celtic Pharma Management L.P. He served as a Director of Questcor Pharmaceuticals, Inc. since June 2013 until August 2014. He served as a Director of Shire plc from December 13, 1999 to April 30, 2013. He served as a Director of InterMune, Inc. from October 31, 2011 to September 29, 2014. Mr. Russell served as a Non-Executive Director of The City of London Investment Trust plc from July 1, 2003 to June 30, 2009. He served as a Trustee Director of the ZENECA UK Pension Fund. He was the Chairman of the Society of International Treasurers. Mr. Russell is a Member of the Institute of Chartered Accountants in England and Wales. He is a Fellow of the Association of Corporate Treasurers. He is a Chartered Accountant, having qualified with Coopers & Lybrand (now PricewaterhouseCoopers LLP). Mr. Russell holds Honorary Doctor of Business Administration from Coventry University, U.K. He is an Independent Director of Structure Therapeutics Inc. from August 2024.

Positions